AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23570290
Drug: NAL‐NL1 prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAL‐NL1 prescription
Trial: 22122291
Drug: Cue exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cue exposure treatment-food
Trial: 18210717
Drug: Fixed drug
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed drug combination RMP300 HIN150 (20 patients)
Trial: 18210717
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug tablets (RMP and HIN) (18 patients)
Trial: 18210717
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (20 patients with fixed drug combination and 18 patients with single drug tablets)
Trial: 7803946
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (specifics not detailed, but mentions diuretics and beta-adrenergic blocking drugs)
Trial: 7803946
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (ACE inhibitors and calcium channel blockers)
Trial: 2468858
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg (acute oral administration)
Trial: 2468858
Drug: Nitrendipine 10
RxNorm normalized name: nitrendipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 10 mg b.i.d. (chronic oral administration)
Trial: 28063325
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo NRT sampling (patch, gum, combination NRT)
Trial: 25051390
Drug: Caffeinated energy
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated energy drink (3 mg·kg of caffeine)
Trial: 23541416
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (ganirelix 0.25mg daily)
Trial: 20716145
Drug: Amlodipine/valsartan (Aml/Val)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan (Aml/Val) combination therapy, low dose (2.5/80 mg, titrated to 5/160 mg or 10/160 mg)
Trial: 20716145
Drug: Amlodipine/valsartan (Aml/Val)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan (Aml/Val) combination therapy, high dose (5/80 mg, titrated to 5/160 mg or 10/160 mg)
Trial: 20716145
Drug: Amlodipine/valsartan (Aml/Val)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan (Aml/Val) combination therapy with optional hydrochlorothiazide (HCTZ) 12.5 mg
Trial: 20716145
Drug: Amlodipine/valsartan (Aml/Val)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan (Aml/Val) combination therapy, low dose
Trial: 20716145
Drug: Amlodipine/valsartan (Aml/Val)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan (Aml/Val) combination therapy, high dose
Trial: 18156922
Drug: Intra-arterial iodine-131-labeled
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial iodine-131-labeled lipiodol (1850 MBq dose)
Trial: 12911824
Drug: Serrapeptase (SER)
DrugBank: Serrapeptase (DB13131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serrapeptase (SER) 30 mg/day for 4 weeks
Trial: 7421183
Drug: Biofeedback-relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback-relaxation therapy (30 1-hour training sessions over a 13-week period)
Trial: 7421183
Drug: Biofeedback-relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback-relaxation therapy (after 3 months of control)
Trial: 7421183
Drug: Biofeedback-relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback-relaxation therapy
Trial: 31430226
Drug: Pyrotinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib (400 mg orally once per day) combined with capecitabine (1,000 mg/m2 orally twice per day on days 1 to 14)
Trial: 31430226
Drug: Lapatinib (1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1,250 mg orally once per day) combined with capecitabine (1,000 mg/m2 orally twice per day on days 1 to 14)
Trial: 23448616
Drug: Ticagrelor (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (450 mg single dose, 180 mg 12 hours later, twice daily for 2 days, and once on day 4)
Trial: 15169685
Drug: NK(3) antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NK(3) antagonist (SR142801)
Trial: 15169685
Drug: 5‐HT(2A/2C) antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT(2A/2C) antagonist (SR46349B)
Trial: 15169685
Drug: CB(1) antagonist
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB(1) antagonist (SR141716)
Trial: 15169685
Drug: NTS(1) antagonist
RxNorm normalized name: NT-219
DrugBank: NT-219 (DB17490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTS(1) antagonist (SR48692)
Trial: 1201184
Drug: Potassium supplements
RxNorm normalized name: POTASSIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium supplements
Trial: 1201184
Drug: Prednisone (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (without potassium supplements)
Trial: 26149441
Drug: Kokoro-App plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kokoro-App plus switching antidepressant
Trial: 26149441
Drug: Switching antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching antidepressant alone
Trial: 21275440
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride 60 mg XR
Trial: 19738015
Drug: Boost Plus
RxNorm normalized name: Boost Plus Vanilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boost Plus 8 oz (240 ml)
Trial: 19738015
Drug: Boost Plus
RxNorm normalized name: Boost Plus Vanilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boost Plus 4 oz (120 ml)
Trial: 19738015
Drug: Boost Plus
RxNorm normalized name: Boost Plus Vanilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boost Plus 2 oz (60 ml)
Trial: 19738015
Drug: Boost Plus
RxNorm normalized name: Boost Plus Vanilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boost Plus 1 oz (30 ml)
Trial: 17803714
Drug: Misoprostol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (600 micrograms oral)
Trial: 15167287
Drug: Atazanavir 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 400 mg
Trial: 15167287
Drug: Atazanavir 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 600 mg
Trial: 15167287
Drug: Nelfinavir-to-atazanavir switch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir-to-atazanavir switch (400 mg)
Trial: 9514180
Drug: Cicletanine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine (50 mg daily, orally)
Trial: 7995312
Drug: Hydrochlorothiazide added
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide added to Lisinopril
Trial: 26751191
Drug: NBI-77860 300
RxNorm normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI-77860 300 mg
Trial: 26751191
Drug: NBI-77860 600
RxNorm normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI-77860 600 mg
Trial: 17616002
Drug: CCGC (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCGC (combined capsaicin, green tea extract, and chicken essence tablets)
Trial: 16095444
Drug: Epidural lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural lidocaine (2% lidocaine, 15 ml, maintenance infusion rate of 6 ml h‐1)
Trial: 16095444
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia alone (normal saline, 15 ml, maintenance infusion rate of 6 ml h‐1)
Trial: 9862538
Drug: Phenol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenol (3 ml of 5% phenol via tibial nerve blockade)
Trial: 2576432
Drug: 1% D-timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% D-timolol (topical administration)
Trial: 27719741
Drug: GSK2647544 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2647544 (0.5 - 750 mg single escalating oral doses)
Trial: 27719741
Drug: GSK2647544 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2647544 (80 mg repeat doses)
Trial: 23455596
Drug: Caffeine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (80 mg) with water
Trial: 23455596
Drug: Caffeine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (80 mg) with yoghurt-based drink
Trial: 23455596
Drug: Caffeine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (80 mg) with glucose-based drink
Trial: 23455596
Drug: Caffeine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (80 mg) irrespective of vehicle
Trial: 16963034
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release metformin
Trial: 10939702
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen 400 mg
Trial: 10939702
Drug: Oral dextromethorphan
RxNorm normalized name: dextromethorphan Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dextromethorphan 120 mg
Trial: 10939702
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ibuprofen 400 mg and dextromethorphan 120 mg
Trial: 1350481
Drug: Carvedilol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (100 mg)
Trial: 4007027
Drug: Bay g
RxNorm normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bay g 2821 (muzolimine)
Trial: 27663186
Drug: Symptom management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom management (SM) drugs
Trial: 27663186
Drug: Disease management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease management (DM) drugs
Trial: 18162083
Drug: IV esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV esomeprazole 40 mg
Trial: 18162083
Drug: IV lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lansoprazole 30 mg
Trial: 11111131
Drug: Whole-leaf spinach,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-leaf spinach, minced spinach, liquefied spinach, liquefied spinach with dietary fibre (10 g/kg wet weight)
Trial: 11111131
Drug: Synthetic carotenoid
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic carotenoid supplement
Trial: 8617114
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (bismuth, metronidazole, tetracycline) for one week
Trial: 8617114
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (amoxicillin and omeprazole) for two weeks
Trial: 22971493
Drug: L-CCB
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-CCB
Trial: 16085251
Drug: Lumbar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar epidural tramadol (100 mg)
Trial: 16085251
Drug: Lumbar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar epidural morphine (4 mg)
Trial: 9053503
Drug: Etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide phosphate (EP) at 10 mg/m2/d
Trial: 9053503
Drug: Etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide phosphate (EP) at 20 mg/m2/d
Trial: 9053503
Drug: Etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide phosphate (EP) at 25 mg/m2/d
Trial: 9053503
Drug: Etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide phosphate (EP) at 30 mg/m2/d
Trial: 3940830
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline (100 mg) with T.E.
Trial: 3940830
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline (200 mg) with T.E.
Trial: 3940830
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline (351 mg) with T.E.
Trial: 3940830
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline (200 mg) with T.P.D.
Trial: 29402513
Drug: Autologous platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet-rich fibrin (PRF) placed in the peri-implant region (n=21)
Trial: 29402513
Drug: No augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No augmentation (control group, n=20)
Trial: 27737744
Drug: Canakinumab 150
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 mg monthly for 12 months
Trial: 24795254
Drug: RO5093151 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO5093151 (200 mg twice daily)
Trial: 23103618
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of modafinil orally
Trial: 18595969
Drug: Placebo (oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oil droplets from gelatinous capsule)
Trial: 16080445
Drug: Food supplemented
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplemented with vitamin C (from kiwi fruits) and vitamin E (in capsules)
Trial: 12565115
Drug: Sufentanil bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil bolus at 0.5 microg kg(‐1) and continuous infusion at 0.5 microg kg h(‐1) stopped when the tourniquet was released (Group 1, n=6)
Trial: 12565115
Drug: Sufentanil bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil bolus at 0.5 microg kg(‐1) and continuous infusion at 0.5 microg kg h(‐1) stopped 15 minutes after tourniquet release (Group 2, n=6)
Trial: 30346860
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg OD at 8:00 AM
Trial: 30346860
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg OD at 8:00 PM
Trial: 30346860
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg BID at 8:00 AM and PM
Trial: 23357031
Drug: Ethanol at
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol at BAC levels of 0.5g/L and 0.9g/L
Trial: 23357031
Drug: Placebo drinks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drinks and placebo pills
Trial: 9570192
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone replacement therapy
Trial: 3054626
Drug: Amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 25 mg bid
Trial: 31904760
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (60 g/day) with high-fiber wheat bran (30 g fiber/day)
Trial: 31904760
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (60 g/day) with low-fiber refined wheat (10 g fiber/day)
Trial: 31904760
Drug: Maltodextrin with
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin with high-fiber wheat bran (30 g fiber/day)
Trial: 31904760
Drug: Maltodextrin with
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin with low-fiber refined wheat (10 g fiber/day)
Trial: 12706935
Drug: Bosentan (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (125 or 250 mg twice daily)
Trial: 11022397
Drug: Tropicamide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropicamide (20 microL, 0.01%) administered to one eye and placebo to the other.
Trial: 11022397
Drug: Scopolamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.5 mg, intravenously) administered in separate sessions.
Trial: 8612392
Drug: Phenytoin 300
RxNorm normalized name: phenytoin 300 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin 300 mg daily
Trial: 6692384
Drug: Hydrazine sulfate
RxNorm normalized name: Hydrazine Sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrazine sulfate (60 mg, 3 times/day for 30 days)
Trial: 29122709
Drug: Letrozole (10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (10mg daily for 3 days) followed by vaginal misoprostol
Trial: 23282127
Drug: Nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5 mg per day)
Trial: 27113048
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate (100 mg per day)
Trial: 23707383
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT), n=50
Trial: 12821232
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 0.5 mg/day
Trial: 10826403
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 to 10 mg daily)
Trial: 30570309
Drug: CBTsa (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBTsa (Cognitive Behavioral Therapy for social activation)
Trial: 26016955
Drug: Grief intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Grief intervention treatment group
Trial: 21276961
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin monotherapy (48 weeks; n=31)
Trial: 12743670
Drug: Quinine hydrochloride
RxNorm normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine hydrochloride 250 mg alone
Trial: 12743670
Drug: Quinine hydrochloride
RxNorm normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine hydrochloride 250 mg with four other CYP probe drugs
Trial: 12743670
Drug: Quinine hydrochloride
RxNorm normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine hydrochloride 250 mg with ketoconazole
Trial: 12743670
Drug: Quinine hydrochloride
RxNorm normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine hydrochloride 250 mg with fluvoxamine
Trial: 29338584
Drug: βHB salts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: βHB salts (0.38 g kg body mass‐1) in plain water (3.8 mL kg body mass‐1)
Trial: 29338584
Drug: plain water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plain water (3.8 mL kg body mass‐1) (CON)
Trial: 21368750
Drug: rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 4 mg b.i.d. for 9 weeks
Trial: 16490809
Drug: Ezetimibe (EZE)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (EZE) 10 mg coadministered with CyA (75-150 mg twice a day)
Trial: 16490809
Drug: Ezetimibe (EZE)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (EZE) 10 mg with CyA
Trial: 14508021
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (received information about pain relieving injection)
Trial: 14508021
Drug: Nocebo group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocebo group (received information about pain increasing injection)
Trial: 14508021
Drug: Natural History
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural History group (received no information and no injection)